205 related articles for article (PubMed ID: 19562469)
1. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469
[TBL] [Abstract][Full Text] [Related]
2. Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.
Xu XS; Yuan M; Yang H; Feng Y; Xu J; Pinheiro J
AAPS J; 2017 Jan; 19(1):264-273. PubMed ID: 27761720
[TBL] [Abstract][Full Text] [Related]
3. Covariate detection in population pharmacokinetics using partially linear mixed effects models.
Bonate PL
Pharm Res; 2005 Apr; 22(4):541-9. PubMed ID: 15846461
[TBL] [Abstract][Full Text] [Related]
4. Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models.
Bertrand J; Comets E; Chenel M; Mentré F
Biometrics; 2012 Mar; 68(1):146-55. PubMed ID: 22049987
[TBL] [Abstract][Full Text] [Related]
5. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
Bertrand J; Comets E; Mentre F
J Biopharm Stat; 2008; 18(6):1084-102. PubMed ID: 18991109
[TBL] [Abstract][Full Text] [Related]
6. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
[TBL] [Abstract][Full Text] [Related]
7. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
Bazzoli C; Retout S; Mentré F
Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
[TBL] [Abstract][Full Text] [Related]
8. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
9. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
[TBL] [Abstract][Full Text] [Related]
10. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.
Retout S; Comets E; Samson A; Mentré F
Stat Med; 2007 Dec; 26(28):5162-79. PubMed ID: 17486667
[TBL] [Abstract][Full Text] [Related]
11. Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.
Savic RM; Mentré F; Lavielle M
AAPS J; 2011 Mar; 13(1):44-53. PubMed ID: 21063925
[TBL] [Abstract][Full Text] [Related]
12. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
Panhard X; Mentré F
Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
[TBL] [Abstract][Full Text] [Related]
13. Optimization of individual and population designs using Splus.
Retout S; Mentré F
J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):417-43. PubMed ID: 15000423
[TBL] [Abstract][Full Text] [Related]
14. The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.
Samson A; Lavielle M; Mentré F
Stat Med; 2007 Nov; 26(27):4860-75. PubMed ID: 17562540
[TBL] [Abstract][Full Text] [Related]
15. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.
Comets E; Verstuyft C; Lavielle M; Jaillon P; Becquemont L; Mentré F
Eur J Clin Pharmacol; 2007 May; 63(5):437-49. PubMed ID: 17404720
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of estimation methods and power of tests of discrete covariates in repeated time-to-event parametric models: application to Gaucher patients treated by imiglucerase.
Vigan M; Stirnemann J; Mentré F
AAPS J; 2014 May; 16(3):415-23. PubMed ID: 24570340
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model.
Gibiansky L; Gibiansky E; Bauer R
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):17-35. PubMed ID: 22101761
[TBL] [Abstract][Full Text] [Related]
18. Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Panhard X; Taburet AM; Piketti C; Mentré F
Stat Med; 2007 Mar; 26(6):1268-84. PubMed ID: 16810714
[TBL] [Abstract][Full Text] [Related]
19. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
Silber HE; Kjellsson MC; Karlsson MO
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):81-99. PubMed ID: 19219538
[TBL] [Abstract][Full Text] [Related]
20. Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.
Combes FP; Retout S; Frey N; Mentré F
CPT Pharmacometrics Syst Pharmacol; 2014 Apr; 3(4):e109. PubMed ID: 24717242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
